Alnylam Pharmaceuticals | ALNY - Cash And Equivalent


Alnylam Pharmaceuticals reported $1.71B in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
Agios Pharmaceuticals USD 113.6M 24.47M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 53.53M Mar/2026
Amgen USD 12.04B 2.91B Mar/2026
Arrowhead Research USD 201.64M 112.94M Dec/2025
BioCryst Pharmaceuticals USD 171.59M 164.32M Mar/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Incyte USD 4.02B 435.22M Mar/2026
Ionis Pharmaceuticals USD 1.92B 758M Mar/2026
Moderna USD 1.91B 687M Mar/2026
Neurocrine Biosciences USD 266.5M 446.5M Mar/2026
Novartis USD 9.56B 2.9B Sep/2025
PTC Therapeutics USD 833.99M 150.66M Mar/2026
Regeneron Pharmaceuticals USD 2.96B 15.9B Mar/2026
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 464.45M 336.83M Mar/2026
Takeda JPY 654.94B 26.55B Dec/2025
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Ultragenyx Pharmaceutical USD 175M 246M Mar/2026
Vertex Pharmaceuticals USD 7.25B 638.6M Mar/2026
Xencor USD 14.17M 39.9M Mar/2026